APAC Thyroid cancer Market

APAC Thyroid Cancer Market Size (2023 to 2028)

As per our report, the size of the Asia Pacific Thyroid Cancer Market was valued at USD 60.37 million in 2023 and is expected to grow at a CAGR of 30.16% to reach USD 225.53 million by 2028.

Thyroid cancer is becoming more common, and there is a greater emphasis on early detection and treatment, which is projected to boost market expansion. Thyroid cancer is a very rare malignancy, yet technologically advanced diagnostic methods have expanded incidence rates in recent years. Factors driving the market include an increase in thyroid cases, an increasing number of government initiatives, and increased investment in research and technological advancements in cancer diagnosis and treatment.

One of the primary factors driving the growth of the Asia Pacific thyroid cancer market is the rise in the number of neuroendocrine tumor cases among the population. It is also accelerated by increased investment in research and development efforts to improve the overall course of diagnosis and treatment of thyroid cancer and expand awareness of therapy and technological improvement. The rise in the number of obese people and the adoption of hazardous lifestyle habits such as junk food and alcohol consumption have a different influence on the thyroid cancer market. Furthermore, an increase in money for treatment from for-profit and nonprofit organizations and an increase in healthcare spending and government assistance have a beneficial impact on the thyroid cancer market in the APAC region.

However, the market's expansion is being stifled by a lack of knowledge regarding the actual causal causes and late detection of the disease. In addition, thyroid cancer market growth is projected to be hampered by the patent expiration of patented drugs, the advent of generic versions of branded drugs, and the high cost of treatment. In the forecast period, the thyroid cancer market is expected to be challenged by a lack of competent specialists and awareness about therapies in this country.

This research report on the Asia Pacific thyroid cancer market has been segmented and sub-segmented into the following categories.

By Treatment:

• Surgery
• Iodine Therapy
• External Therapy
• Thyroxine treatment
• Chemotherapy
• Drugs

By Drug: 

• Levothyroxine
• Radioiodine

By End User: 

• Hospitals
• Oncology Centres
• Hospital Pharmacies
• Retail Pharmacies

By Country: 

• India
• China
• Japan
• South Korea
• Australia
• New Zealand
• Thailand
• Malaysia
• Vietnam
• Philippines
• Indonesia
• Singapore
• Rest of APAC

Because of the rising investment in R&D for the development of new pharmaceuticals and techniques for thyroid cancer therapy in the area, the market in the Asia Pacific is expected to grow at the fastest CAGR over the forecast period. The market in the Asia Pacific is expected to grow at the quickest rate throughout the forecast period because of factors such as rising thyroid cancer prevalence, higher consumer awareness, improved healthcare infrastructure, and increased disposable income. During the projection period, the market for thyroid cancer diagnostics in growing countries such as China, India, and South Korea is likely to grow rapidly. Thyroid cancer diagnostics may experience substantial expansion in Asia-Pacific as well, given the region's rapid development and the government's efforts to raise awareness about the condition. This market is becoming increasingly competitive as significant companies focus on strategic efforts such as product launches and development, mergers and acquisitions, licensing alliances, and co-development deals. Furthermore, numerous healthcare companies invest in this region, and the regional population's disposable income is rising. As a result of all factors, the thyroid cancer market in Asia-Pacific is expected to increase in the next few years.

KEY MARKET PLAYERS:

Noteworthy players dominating the APAC Thyroid Cancer Market profiled in this report are Baxter International Inc., Mylan Pharmaceuticals Inc., Alara Pharmaceutical Corporation, Bristol Myers co, Abbott laboratories, Teva parenteral medicines Inc., App pharmaceuticals LLC, and Jerome Stevens Pharmaceuticals Inc.